Urine (Amsterdam, Netherlands)最新文献

英文中文

Evaluation of the multicenter variations of urinary metabolomics 尿代谢组学多中心变异的评价

Urine (Amsterdam, Netherlands)

Pub Date : 2019-06-01 DOI: 10.1016/j.urine.2020.05.004

Jing Li , Haidan Sun , Xiaoyan Liu , Qinghong Shi , Lu He , Yulin Sun , Chengyan He , Yajie Wang , Xiaohang Zhao , Lihua Fan , Zhengguang Guo , Shirley X. Tsang , Wei Sun

Background

Multicenter experiments have frequently been performed in clinical biomarker studies. However, center effects should not be ignored. In this study, for the first time,we estimated the multicenter variations of the urinary metabolome in China.

Methods

In this study, midstream urine samples from a total of 83 healthy individuals were collected in four centers in Beijing and Changchun. Liquid chromatography-high resolution mass spectrometry -based metabolomics was used to analyze the differences among the four centers.

Results

Within the same city, there were significant variations in the urinary metabolome among the three centers. Different centers had unique differential metabolites. Amino acids, N-acetylglucosamine, glutathione, and NAD metabolism contributed to the multicenter variation. The metabolomics variation between Beijing and Changchun was obviously higher than that within the same city (Beijing). The variations between Beijing and Changchun were associated with tetrapyrrole metabolism, hememetabolism, and eicosanoid signaling.

Conclusions

This study provides insights into the center and regional effect of the urinary metabolome in China. Our results might benefit the experimental design of multicenter urinary metabolome research in the clinic.

临床生物标志物研究中经常进行多中心实验。然而，中心效应不应该被忽视。在这项研究中，我们首次估计了中国尿代谢组的多中心变异。方法在北京和长春4个中心采集83例健康人中游尿液样本。采用液相色谱-高分辨率质谱代谢组学分析4个中心之间的差异。结果在同一城市内，三个中心的尿代谢组存在显著差异。不同的中心有独特的代谢物差异。氨基酸、n -乙酰氨基葡萄糖、谷胱甘肽和NAD代谢导致了多中心变异。北京和长春的代谢组学差异明显高于同一城市(北京)内的差异。北京和长春之间的差异与四吡咯代谢、血液代谢和类二十烷信号传导有关。结论本研究揭示了尿代谢组学在中国的中心效应和区域效应。本研究结果可为临床多中心尿液代谢组研究的实验设计提供参考。

{"title":"Evaluation of the multicenter variations of urinary metabolomics","authors":"Jing Li , Haidan Sun , Xiaoyan Liu , Qinghong Shi , Lu He , Yulin Sun , Chengyan He , Yajie Wang , Xiaohang Zhao , Lihua Fan , Zhengguang Guo , Shirley X. Tsang , Wei Sun","doi":"10.1016/j.urine.2020.05.004","DOIUrl":"10.1016/j.urine.2020.05.004","url":null,"abstract":"<div><h3>Background</h3><p>Multicenter experiments have frequently been performed in clinical biomarker studies. However, center effects should not be ignored. In this study, for the first time,we estimated the multicenter variations of the urinary metabolome in China.</p></div><div><h3>Methods</h3><p>In this study, midstream urine samples from a total of 83 healthy individuals were collected in four centers in Beijing and Changchun. Liquid chromatography-high resolution mass spectrometry -based metabolomics was used to analyze the differences among the four centers.</p></div><div><h3>Results</h3><p>Within the same city, there were significant variations in the urinary metabolome among the three centers. Different centers had unique differential metabolites. Amino acids, N-acetylglucosamine, glutathione, and NAD metabolism contributed to the multicenter variation. The metabolomics variation between Beijing and Changchun was obviously higher than that within the same city (Beijing). The variations between Beijing and Changchun were associated with tetrapyrrole metabolism, hememetabolism, and eicosanoid signaling.</p></div><div><h3>Conclusions</h3><p>This study provides insights into the center and regional effect of the urinary metabolome in China. Our results might benefit the experimental design of multicenter urinary metabolome research in the clinic.</p></div>","PeriodicalId":75287,"journal":{"name":"Urine (Amsterdam, Netherlands)","volume":"1 ","pages":"Pages 29-34"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.urine.2020.05.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48664438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Era of URINE 尿的时代

Urine (Amsterdam, Netherlands)

Pub Date : 2019-06-01 DOI: 10.2139/ssrn.3502009

Youhe Gao

Urine has been considered to be able to reflect diseases since ancient time. But the era of urine never comes. Blood is thought to connect with all the organs and exchange materials with them. Blood is stable. Any changes happened in blood are believed more reliable, at least compare to urine. In the history of medicine, this period of time is the era of blood. In this period of medicine history, early diagnosis is still hard, still not early enough to stop many diseases to save lives. Researchers are trying very hard to make machines and assays to be more sensitive. Many many people are still suffering and even dying because of late diagnosis. A new urimarker theory sheds some light on this wondering field. The theory starts with the analysis of the biomarker experiments design. In all the biomarker studies, there are at least two groups of samples. No matter what are measured, the values of the two groups are compared to find the differences, the changes. From this common scheme, change is emphasized in a new biomarker definition, which is, biomarker is the measurable changes associated with the disease. With this new definition in mind,it is not difficult to reason where we should be looking for these changes. The concept of the regulation of the internal environment was described by French physiologist Claude Bernard in 1865, and the word homeostasis was coined by Walter Bradford Cannon in 1926. Based on the homeostasis of internal environment theory, biomarker, which is change, should be found earlier and more sensitively in urine,which is full of changes, rather than blood, which is rather stable in the early phase of disease processes. The reason we failed to realize the potential of urine was because almost all the studies were done in clinical samples. Many confounding factors were not even considered. And with so many factors to balance, the sample size was never large enough to reach verifiable results. The roadmap of urimarker was then proposed to start the discovery phase with animal models. Confounding factors are minimized. Now more and more evidences that support this urimarker theory are emerging in animal model studies.

自古以来，人们就认为尿液可以反映疾病。但是尿的时代永远不会到来。血液被认为与所有器官相连，并与它们交换物质。血液稳定。血液中的任何变化都被认为是更可靠的，至少与尿液相比。在医学史上，这段时间是血液的时代。在这一时期的医学史上，早期诊断仍然很困难，仍然不足以早期阻止许多疾病以挽救生命。研究人员正在努力使机器和检测方法更加灵敏。由于诊断晚了，许多人仍在受苦，甚至死亡。一种新的无标记理论为这个令人困惑的领域提供了一些启示。本理论从生物标志物实验设计的分析入手。在所有的生物标志物研究中，至少有两组样本。无论测量什么，比较两组的值，找出差异，变化。从这个共同的方案中，新的生物标志物定义强调了变化，即生物标志物是与疾病相关的可测量的变化。有了这个新的定义，就不难推断出我们应该在哪里寻找这些变化了。1865年，法国生理学家克劳德·伯纳德(Claude Bernard)提出了调节内部环境的概念，1926年，沃尔特·布拉德福德·坎农(Walter Bradford Cannon)创造了“内稳态”(homeostasis)一词。基于内环境稳态理论，生物标志物(即变化)应该在尿液中更早、更敏感地被发现，因为尿液中充满了变化，而血液在疾病过程的早期阶段相对稳定。我们之所以没有意识到尿液的潜力，是因为几乎所有的研究都是在临床样本中进行的。甚至没有考虑到许多混杂因素。由于有如此多的因素需要平衡，样本量从来没有大到足以得出可验证的结果。然后提出了urimark的路线图，以开始动物模型的发现阶段。混淆因素被最小化。在动物模型研究中，越来越多的证据支持这一理论。

{"title":"Era of URINE","authors":"Youhe Gao","doi":"10.2139/ssrn.3502009","DOIUrl":"https://doi.org/10.2139/ssrn.3502009","url":null,"abstract":"Urine has been considered to be able to reflect diseases since ancient time. But the era of urine never comes. Blood is thought to connect with all the organs and exchange materials with them. Blood is stable. Any changes happened in blood are believed more reliable, at least compare to urine. In the history of medicine, this period of time is the era of blood. In this period of medicine history, early diagnosis is still hard, still not early enough to stop many diseases to save lives. Researchers are trying very hard to make machines and assays to be more sensitive. Many many people are still suffering and even dying because of late diagnosis. A new urimarker theory sheds some light on this wondering field. The theory starts with the analysis of the biomarker experiments design. In all the biomarker studies, there are at least two groups of samples. No matter what are measured, the values of the two groups are compared to find the differences, the changes. From this common scheme, change is emphasized in a new biomarker definition, which is, biomarker is the measurable changes associated with the disease. With this new definition in mind,it is not difficult to reason where we should be looking for these changes. The concept of the regulation of the internal environment was described by French physiologist Claude Bernard in 1865, and the word homeostasis was coined by Walter Bradford Cannon in 1926. Based on the homeostasis of internal environment theory, biomarker, which is change, should be found earlier and more sensitively in urine,which is full of changes, rather than blood, which is rather stable in the early phase of disease processes. The reason we failed to realize the potential of urine was because almost all the studies were done in clinical samples. Many confounding factors were not even considered. And with so many factors to balance, the sample size was never large enough to reach verifiable results. The roadmap of urimarker was then proposed to start the discovery phase with animal models. Confounding factors are minimized. Now more and more evidences that support this urimarker theory are emerging in animal model studies.","PeriodicalId":75287,"journal":{"name":"Urine (Amsterdam, Netherlands)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48959468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Era of URINE 尿的时代

Urine (Amsterdam, Netherlands)

Pub Date : 2019-06-01 DOI: 10.1016/j.urine.2019.04.001

Youhe Gao

引用次数: 0

Human Urine Proteome: A Powerful Source for Clinical Research 人类尿液蛋白质组:临床研究的有力来源

Urine (Amsterdam, Netherlands)

Pub Date : 2019-01-01 DOI: 10.1007/978-981-13-9109-5_2

Xiaolian Xiao, Lili Zou, Wei Sun

引用次数: 1

Comparison of Urinary Proteomes Among Three Animal Models 三种动物模型尿液蛋白质组的比较

Urine (Amsterdam, Netherlands)

Pub Date : 2019-01-01 DOI: 10.1007/978-981-13-9109-5_3

Naumenko Ni, Jianqiang Wu

引用次数: 0

Application of Urine Proteome in Cardiac Diseases Biomarker Discovery 尿蛋白质组在心脏疾病生物标志物发现中的应用

Urine (Amsterdam, Netherlands)

Pub Date : 2019-01-01 DOI: 10.1007/978-981-13-9109-5_14

Mindi Zhao

引用次数: 0

Urine Is Not a Human Waste but a Medical Treasure 尿液不是人类的废物，而是医学的瑰宝

Urine (Amsterdam, Netherlands)

Pub Date : 2019-01-01 DOI: 10.1007/978-981-13-9109-5_1

Youhe Gao

引用次数: 0

Urimem, a Membrane that Stores Urinary Components for Large-Scale Biomarker Study 尿膜:用于大规模生物标志物研究的储存尿液成分的膜

Urine (Amsterdam, Netherlands)

Pub Date : 2019-01-01 DOI: 10.1007/978-981-13-9109-5_4

Lulu Jia, Fanshuang Zhang, Weiwei Qin

引用次数: 0

Candidate Urinary Biomarker Discovery in Gliomas 神经胶质瘤中候选尿液生物标志物的发现

Urine (Amsterdam, Netherlands)

Pub Date : 2019-01-01 DOI: 10.1007/978-981-13-9109-5_10

Jianqiang Wu, Yanying Ni

引用次数: 0

Posttranslation Modifications of Human Urine 人类尿液的翻译后修饰

Urine (Amsterdam, Netherlands)

Pub Date : 2019-01-01 DOI: 10.1007/978-981-13-9109-5_5

Weiwei Qin, Mingshan Wang

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Urine (Amsterdam, Netherlands)

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀